Abel Hall LLC
VRTX icon

Abel Hall LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Abel Hall LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$571K Buy
1,092
+42
+4% +$21.5K 0.1% 176
2026
Q2 		$522K Sell
1,050
-424
-29% -$188K 0.09% 227
2026
Q1 		$658K Buy
1,474
+114
+8% +$53.2K 0.14% 129
2025
Q4 		$617K Buy
+1,360
New +$586K 0.14% 118
2025
Q3 		– Sell
-521
Closed -$232K – 358
2025
Q2 		$232K Sell
521
-47
-8% -$21.7K 0.11% 205
2025
Q1 		$275K Buy
568
+46
+9% +$21.4K 0.17% 114
2024
Q4 		$210K Buy
522
+40
+8% +$18.5K 0.13% 128
2024
Q3 		$224K Buy
482
+12
+3% +$5.76K 0.15% 125
2024
Q2 		$220K Buy
+470
New +$204K 0.16% 113

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

Abel Hall LLC's VRTX Position: Q3 2026 in Review

Abel Hall LLC increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q3 2026, buying an estimated $21.5K and bringing the position to 1,092 shares worth $571K. The position accounts for 0.1% of the portfolio, ranked #176.

Abel Hall LLC first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $658K in Q1 2026. 576 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Abel Hall LLC held 1,092 shares of Vertex Pharmaceuticals worth $571K as of Q3 2026.
  • Abel Hall LLC bought 42 Vertex Pharmaceuticals shares in Q3 2026, an estimated $21.5K.
  • Vertex Pharmaceuticals made up 0.1% of Abel Hall LLC's portfolio in Q3 2026, its #176 holding.
  • Abel Hall LLC first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Abel Hall LLC's Vertex Pharmaceuticals position peaked at $658K in Q1 2026.
  • 576 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.